
Memorial Sloan Kettering Cancer Center
- 2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis
- Myeloma
- Leukemia
- Lymphoma
- Hematologic Transplantation and Malignancies
- Breast
- Lung
- Gastrointestinal
- Genitourinary
- Gynecologic
- Skin
- Head and Neck
- Brain
- General Oncology
- Palliative Care
- MPN
- COVID-19
- Events
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
0:00
Stream Type LIVE
Remaining Time -0:00
1x
- 0.5x
- 0.75x
- 1x, selected
- 1.25x
- 1.5x
- 1.75x
- 2x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
10 seconds
Playback speed
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
ASCO 2022 HR+ Breast Cancer Updates
By
Nebraska Oncology Society
FEATURING
Chau Dang
By
Nebraska Oncology Society
FEATURING
Chau Dang
601 views
July 6, 2022
This presentation was recorded prior to fam-trastuzumab deruxtecan-nxki (Enhertu) receiving FDA approval on August 5, ...
read more ↘ 2022, for adult patients with HER2-low MBC who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.
↖ read less
read more ↘ 2022, for adult patients with HER2-low MBC who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.
↖ read less
Comments 0
Login to view comments.
Click here to Login